JPM Meeting Notes – Actinium Pharmaceuticals (ATNM)

During my meeting with Actinium Pharmaceuticals (ATNM) we delved deeper into the topic I covered via a separate article last week – the clinical hold placed on Seattle Genetics SGN-CD33A. I can go into a lot more detail if necessary, but I think if investors read that article above they will get the picture. I do not believe there is a meaningful risk of hepatotoxicity or VDO with Iomab-B or Actimab-A. The problem is that ADCs, for all their promise, just do not seem to be well tolerated.

In the meantime, Actinium has a catalyst-rich year ahead, headlined by at least one DMC analysis on Phase 3 SIERRA (potentially two) and further looks at the ongoing Actimab-A Phase 2 results. Management told me to be on the look-out for a new potential indication for Actimab-A later in the year, but would not spill the beans even though I tried pretty hard to pry it out of them. I’m not expecting that until the second quarter.

The most near-term update from the company may come at the BMT Tandem meeting taking place in February 2017 (#BMT17 ← you heard it hear first). This is the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) – it’s a rowdy bunch. Nevertheless, it’s starting to gain more and more attention from Wall Street. I do not know if we will see any new data from the company at BMT Tandem, but it does make sense for Actinium to establish a presence at the event. After all, it’s the target market for the company’s products.

See also  BrainStorm’s Valuation Doesn’t Reflect Potential Value of NurOwn® Therapy